Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared ...

AZD-9574 is under clinical development by AstraZeneca and currently in Phase II for Non-Small Cell Lung Cancer.

MCLA-145 is under clinical development by Merus and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase ...

Keytruda has beaten Roche’s TIGIT drug candidate at the first interim analysis of a phase 2/3 lung cancer trial, prompting ...

Roche is to end a novel lung cancer treatment trial, the Swiss company confirmed on Thursday, following "disappointing" ...

MLB Draft is less than two weeks away and there's debate over who could go No. 1 overall. Here's what experts are predicting.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 ...

French stocks (.FCHI) , opens new tab advanced for a second day with a 0.6% rise amid intensified ... opens new tab dropped 2 ...

Ipsen expands license agreement with Exelixis for development of Cabometyx in advanced neuroendocrine tumours: Paris Thursday, July 4, 2024, 12:00 Hrs [IST] Ipsen, a global biopha ...

Our analysis found that HCPs reacted as positively to the other two most-discussed lung cancer trials at ASCO 2024 - ADRIATIC ...

Brigade Enterprises advanced 3.45% to Rs 1414.25 after the company announced the signing of a joint development agreement (JDA) for a residential project at West Bangalore's Tumkur Road.